NZYM B Novozymes A/S Class B

Trading statement 9M 2024

Trading statement 9M 2024

Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%.

Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their products and processes healthier and more efficient, with less environmental impact. With 9% organic sales growth after the first nine months, good realization of cost synergies and a solid path to realize sales synergies, Novonesis is setting the foundation for further value creation ahead.”

Pro forma sales performance (9M comments unless otherwise indicated)

Novonesis realized 9% pro forma organic sales growth for the first 9M 2024 (Q3 11%). Volumes increased ~7%, and pricing contributed ~2%. Pro forma sales amounted to EUR 2,964.1 million, an increase of 6% (organic 9%, currency -2%, M&A -1%). Emerging markets grew 14% organically, and developed markets increased 6%. Q3 sales growth was strong and positively impacted by customers' order timing.

  • Food & Health Biosolutions realized pro forma organic sales growth of 8% for 9M 2024 (Q3 11%). Pro forma sales were EUR 1,337.1 million, an increase of 3% (organic 8%, currency -2%, M&A -3% from the merger-related divestment of the lactase enzyme business). Food & Beverages grew 9% (Q3 11%) organically, and Human Health increased 3% (Q3 11%), in line with expectations.
  • Planetary Health Biosolutions realized pro forma organic sales growth of 9% for 9M 2024 (Q3 12%). Pro forma sales were EUR 1,627.0 million, an increase of 8% (organic 9%, currency -1%). Household Care grew 15% (Q3 13%) organically and Agriculture, Energy & Tech grew 7% (Q3 12%) organically.

Reported (IFRS) sales performance (Chr. Hansen included as of January 29, 2024)

Novonesis reported 9% organic sales growth in 9M 2024 according to IFRS reporting. Reported sales in EUR were 2,852.1 million (9M 2023: EUR 1,785.1) million). Please see Appendix 2 for further details.

 Pro formaReported (IFRS)
Organic sales growth, %9M 20249M 2023Q3 2024Q3 20239M 20249M 2023Q3 2024Q3 2023
         
Total sales9%6%11%8%9%5%11%8%
         
Food & Health Biosolutions8%6%11%9%8%-2%11%7%
Food & Beverages9%6%11%9%9%-1%11%7%
Human Health3%6%11%8%6%-7%11%6%
         
Planetary Health Biosolutions9%6%12%8%10%10%12%9%
Household Care15%3%13%6%15%3%13%6%
Agriculture, Energy & Tech7%8%12%8%7%19%12%11%
         



















2024 outlook*

Year-on-year, the second half of the year is expected to grow stronger than the first half. The third quarter sales growth was strong and benefitted from order timing. Following this development, Novonesis now expects full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. Both Food & Health Biosolutions and Planetary Health Biosolutions are expected to grow at around the same level as indicated for the Group.

* The outlook 2024 is based on 12 months’ pro forma numbers for the consolidated business. The 2024 Reported (IFRS) numbers for organic sales growth and adjusted EBITDA margin are expected to be similar, i.e. the same outlook. Refer to Company Announcement no. 21 – June 17, 2024, for further details.



Please read the full announcement in PDF

Attachment



EN
07/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Q3 update: Novonesis delivers strong Q3 results and now expects full-y...

Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the fir...

 PRESS RELEASE

Trading statement 9M 2024

Trading statement 9M 2024 Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%. Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their products and processes healthier and more efficient, with less...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Announcement released on November 4, 2024 at 10:07:51 CET did not include PDF file. Please see the full announcement in the attached PDF file. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen restricted stock units (RSU) program. Please read the full announcement in PDF.

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per October 22, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,548,644 shares, corresponding to 5.02% (previously 4.92%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instru...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch